Follicular lymphoma is clinically heterogenous, and therefore necessitates the identification of prognostic markers to stratify risk groups and optimize clinical management. It is relatively rare in ...

Friedberg noted that chemotherapy combined with an antibody remains a recommended treatment for patients with advanced-stage ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...

Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International ...

—What’s the next step for this patient with a 4-year history of low-grade follicular lymphoma and who now has worsening lymphadenopathy and needs a nap at the end of every work day? A 58-year-old male ...

Patients with high-risk relapsed/refractory follicular lymphoma experienced statistically significant and clinically meaningful responses when treated with lisocabtagene maraleucel (liso-cel; Breyanzi ...

Some patients in remission from the blood cancer called follicular lymphoma can be considered cured, a new small study suggests. Using DNA sequencing, researchers were able to test the patients' blood ...

Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States. Two thousand ...

The FOLL12 study has been conducted with the hypothesis that a fluorodeoxyglucose-positron emission tomography and minimal residual disease response–adapted postinduction management of patients with ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with ...

Lower socioeconomic status is associated with poor survival in lymphoma. Patients with follicular lymphoma (FL) lived longer if they had private insurance, according to a study that examined patient ...

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik ® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on ...